CSL signed two agreements with the Trump administration covering drug pricing and U.S. manufacturing expansion.
The company will align Medicaid drug prices with rates in other developed nations. This move provides greater certainty regarding U.S. drug pricing exposure.
CSL will invest $1.5 billion to expand its Kankakee, Illinois, manufacturing facility. This project aims to increase U.S. production of plasma-derived therapies.
The company reported a significant statutory net loss last fiscal year due to impairments.
CSL expects no material financial impact from these deals in fiscal 2027. Shares rose as investors welcomed the increased regulatory clarity.